On February 17, 2025, the Nanjing (Hong Kong) Science and Technology Innovation Environment Promotion and Exchange Conference was held at the Hong Kong Polytechnic University.At the conference, under the witness of Nanjing Mayor Chen Zhichang and leaders of the Hong Kong Polytechnic University and other leaders from Nanjing and Hong Kong,Eieling Technology and Nanjing Jiangning High-tech Industrial Development Zone Management Committee jointly signed the Eieling Technology Super Factory Project Investment Framework Agreement.Government officials, academic leaders and industry representatives from both places witnessed the signing. This marks that Eieling Technology has officially entered a new stage in the field of chronic liver disease management.
Eieling Technology CEO Jia Xiaojia.Chairman of the Board of Directors of the Hong Kong Polytechnic University, Lam Tai Fai, Mayor of Nanjing, Chen Zhichang, and Deputy Secretary for Innovation, Technology and Industry of the Hong Kong Bureau, Cheung Man Li, delivered speeches at the meeting respectively.
Lam Tai-fai, Chairman of the Council of the Hong Kong Polytechnic University
Chen Zhichang, Mayor of Nanjing
Lillian Cheong Man-lei, Deputy Director of the Innovation, Technology and Industry Bureau of Hong Kong
The meeting was attended by the President of the Hong Kong Polytechnic University, Teng Jinguang, the Dean of the Hong Kong Polytechnic University Nanjing Innovation Institute, Academician Zhang Dan, the Secretary-General of the Nanjing Municipal Government, Hong Lilai, the Director of the Nanjing Science and Technology Bureau, Zhao Chengjun, the Director of the Nanjing Municipal Commerce Bureau, Liu Yonghui, the Director of the Nanjing Foreign Affairs Office (Hong Kong and Macao Affairs Office), Lin Wuping, the Mayor of Nanjing Jianye District, Jia Chen, the Mayor of Nanjing Gulou District, Fang Jing, the Vice President of Southeast University, Sun Litao, and the Vice President of China Pharmaceutical University, Yang Yong.
Innovation breaks through, win-win for all parties
The investment framework agreement for the I-Ling Technology Super Factory Project aims to establish the I-Ling Technology Home Edition Global Super Factory in Jiangning District, Nanjing, and to establish a research and development, registration and production base for its home edition products. This is another important layout of I-Ling in terms of technological innovation and industrial implementation, and also reflects its firm belief and long-term planning for the Nanjing market. Following Hong Kong, Nanjing has become the second benchmark city for liver disease screening established by I-Ling Technology worldwide.
At the same time, Eieling Technology also announced the official launch of the “FattaLab®️” project for self-examination of fatty liver at home, marking that Eieling is continuing to deepen its efforts and has taken another solid step in promoting the field of liver disease health management.
Stick to the original intention and continue to work hard
Eieling Technology Limited was established in 2018, has a research background in the Department of Biomedical Engineering of The Hong Kong Polytechnic University (PolyU), and is registered in Hong Kong Science & Technology Park (HKSTP). Eieling Technology successfully joined the Incu-Bio of HKSTP. It is also the first representative enterprise of industry, academia, and research that has been successfully transformed and planned to be located in Nanjing through the “Nanjing Technology Innovation Institute” jointly built by the Hong Kong Polytechnic University and Nanjing City.
Since its development, the company has always adhered to the strategy of original research and innovation, is deeply engaged in the field of liver disease diagnosis and treatment, and is committed to creating accurate and reliable intelligent liver health diagnosis solutions for global healthcare providers through advanced artificial intelligence algorithms and rich liver disease big data resources. It also continuously improves the accuracy and timeliness of liver health diagnosis to protect human liver health.
Collaborative innovation leads the future
This signing is an important milestone in the development of Eieling Technology. The production, R&D and sales headquarters of Eieling Technology’s marketed product “Liverscan, a handheld wireless liver biomarker” and future products under development will be settled in Jiangning, achieving breakthrough development in key areas. At the same time, relying on the location advantages of Jiangning District, Eieling Technology will carry out more extensive liver disease screening, implement the national tiered diagnosis and treatment system, explore and create the country’s first “community-centered chronic liver disease management demonstration zone”, and provide new application scenarios and solutions for chronic liver disease management.
Nanjing’s Jiangning District, with its superior geographical conditions and rich talent pool, provides fertile soil for the innovative development of Eieling Technology. Eieling Technology’s series of innovative achievements will be industrialized in Nanjing first, which will strongly promote the vigorous development of the regional economy. At the same time, taking this signing as an opportunity, the first landing transformation project between the Hong Kong Polytechnic University and Nanjing Research Institute will also introduce more high-quality Hong Kong medical device projects to Jiangning District, coordinate and promote the agglomeration of industrial projects, and promote the deep integration and coordinated development of the two local industries.
Left 3:Eieling Technology CEO Jia Xiaojia
Right 3:Lu Jinsong, Director of Jiangning High-tech Zone Life Science Industry Investment Promotion Bureau
Left 2: Eieling Technology CEO Jia Xiaojia
Right 2:Zhao Chengjun, Director of Nanjing Science and Technology Bureau
Looking into the future, Eieling Technology will continue to work with all parties, taking the Eieling Nanjing Jiangning District Super Factory as a new starting point, and closely follow the development trend of new quality productivity of medical devices. At the same time, it will continue to give full play to its technological and resource advantages, continuously improve its market competitiveness, write a new chapter in liver disease diagnosis and treatment, and contribute more to the cause of human liver health.
Registration is now open
Eieling Technology Ltd. will provide 500 trial devices free of charge to medical institutions in Nanjing within three years, and will work tirelessly to build Nanjing into a domestic benchmark liver screening city. The realization of this goal is inseparable from the joint efforts of every partner.
We sincerely invite all medical institutions in the city to join us to promote the liver disease screening process in Nanjing and jointly open a new era of liver disease screening.
Scan the QR code below and fill in the registration information. We look forward to your joining.
